Compare RCEL & VANI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RCEL | VANI |
|---|---|---|
| Founded | N/A | 1998 |
| Country | United States | United States |
| Employees | 226 | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 126.8M | 116.4M |
| IPO Year | N/A | 2014 |
| Metric | RCEL | VANI |
|---|---|---|
| Price | $5.07 | $1.38 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 1 |
| Target Price | ★ $7.88 | $3.50 |
| AVG Volume (30 Days) | 358.7K | ★ 624.4K |
| Earning Date | 05-14-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $4,000,000.00 |
| Revenue This Year | $17.17 | N/A |
| Revenue Next Year | $49.82 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.22 | $0.92 |
| 52 Week High | $7.12 | $1.92 |
| Indicator | RCEL | VANI |
|---|---|---|
| Relative Strength Index (RSI) | 62.21 | 54.41 |
| Support Level | $3.47 | $1.17 |
| Resistance Level | $5.32 | $1.58 |
| Average True Range (ATR) | 0.44 | 0.12 |
| MACD | 0.03 | 0.01 |
| Stochastic Oscillator | 65.56 | 42.10 |
Avita is largely a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently used in most of the 140 US burn centers. Despite having product approval in Australia, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region, although international sales, particularly in Japan, are growing. Avita is domiciled, and has its primary listing, in the US.
Vivani Medical Inc is a clinical stage biopharmaceutical company which develops miniature, ultra long-acting subdermal drug implant candidates utilizing its proprietary NanoPortal technology, which is designed to enable reversible, ultra long-acting, near constant-rate delivery of a broad range of medicines to treat chronic diseases. Vivani uses this platform technology to develop, and potentially commercialize, drug implant candidates, alone or in collaboration with pharmaceutical company partners, to address causes of poor clinical outcomes in the treatment of chronic diseases, including medication non-adherence, drug tolerability and administration challenges faced by certain patients. It operates in two segments the Biopharm Division and Neurostimulation Division.